N-isopropyl-3-morpholinopropanamide | 1610609-99-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-isopropyl-3-morpholinopropanamide
• 英文别名: 3-morpholin-4-yl-N-propan-2-ylpropanamide
• CAS: 1610609-99-8
• 化学式: C₁₀H₂₀N₂O₂
• 分子量: 200.281
• InChiKey: KHVXYLFIEGVYPC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  吗啉 、 N-异丙基丙烯酰胺 在 [ADPQ][CH₃COO] 作用下， 反应 3.0h， 以75%的产率得到N-isopropyl-3-morpholinopropanamide
  参考文献：
  名称：

  [ADPQ] [CH 3 COO]：高效，可回收的催化剂，用于在无溶剂条件下进行α，β-不饱和化合物和胺的氮杂迈克尔加成反应

  摘要：

  可循环使用的离子液体[ADPQ] [CH 3 COO]已用作将胺氮杂-迈克尔加成到α，β-不饱和化合物中以生产β-氨基化合物的催化剂。反应在数小时内以高收率完成。离子液体可以循环使用六次而不会明显降低催化活性。

  DOI：

  10.1007/s11164-015-1950-4

文献信息

• Ionic tagged DABCO grafted on magnetic nanoparticles: a water-compatible catalyst for the aqueous aza-Michael addition of amines to α,β-unsaturated amides
  作者：Anguo Ying、Shuo Liu、Yuxiang Ni、Fangli Qiu、Songlin Xu、Wenyuan Tang

  DOI：10.1039/c4cy00232f

  日期：——

  A water compatible DABCO grafted on magnetic nanoparticles with an ionic tag has been developed and used to catalyze the aza-Michael addition.

  一种带有离子标记的DABCO接枝磁性纳米颗粒，可与水相容，已被开发并用于催化氮杂Michael加成反应。
• COMPOUNDS USEFUL FOR INHIBITING CHK1
  申请人：Keegan Kathleen S.

  公开号：US20100105683A1

  公开（公告）日：2010-04-29

  Aryl- and heteroaryl-substituted urea compounds useful in the treatment of diseases and conditions related to DNA damage or lesions in DNA replication are disclosed. Methods of making the compounds, and their use as therapeutic agents, for example, in treating cancer and other diseases characterized by defects in DNA replication, chromosome segregation, or cell division also are disclosed.

  本发明公开了用于治疗与DNA损伤或DNA复制中的损伤有关的疾病和病症的芳基和杂环基取代脲化合物。本发明还公开了制备该化合物的方法以及它们作为治疗剂的用途，例如，在治疗癌症和其他以DNA复制缺陷、染色体分离或细胞分裂为特征的疾病中。
• HEDGEHOG PATHWAY SIGNALING INHIBITORS AND THERAPEUTIC APPLICATIONS THEREOF
  申请人：Suzhou Yunxuan Yiyao Keji Youxian Gongsi

  公开号：US20160024095A1

  公开（公告）日：2016-01-28

  The hedgehog (Hh) signaling pathway is a pathway which regulates patterning, growth and cell migration during embryonic development, but in adulthood is limited to tissue maintenance and repair. Mutational inactivation of the inhibitory pathway components leads to constitutive ligand-independent activation of the Hh signaling pathway, results in cancers such as basal cell carcinoma and medulloblastoma. Ligand-dependent activation of Hh signaling is involved in prostate cancer, pancreatic cancer, breast cancer and some blood cancers. Therefore, inhibition of the aberrant Hh signaling represents a promising approach toward novel anticancer therapy. The present invention provides novel molecules of formula I that inhibit hedgehog pathway signaling and provides therapeutic applications for the treatment of malignancies (basal cell carcinoma, medulloblastoma, glioblastoma, non-small cell lung cancer, prostate cancer, pancreatic cancer, blood cancers, mesenchymal cancers, etc.), prevention of tumor regrowth, sensitization of radio-chemo therapies, and other diseases (inflammation, fibrosis and immune disorders) related to hedgehog signaling.

  刺猬（Hh）信号通路是一种在胚胎发育期间调节模式、生长和细胞迁移的通路，但在成年后仅限于组织维护和修复。抑制通路成分的突变失活导致Hh信号通路的构成性配体无关激活，导致基底细胞癌和髓母细胞瘤等癌症。Hh信号的配体依赖性激活涉及前列腺癌、胰腺癌、乳腺癌和一些血液癌症。因此，抑制异常的Hh信号是一种有前途的新型抗癌治疗方法。本发明提供了公式I的新型分子，可以抑制刺猬通路信号，并提供治疗恶性肿瘤（基底细胞癌、髓母细胞瘤、胶质母细胞瘤、非小细胞肺癌、前列腺癌、胰腺癌、血液癌症、间叶癌症等），预防肿瘤再生长，增强放化疗的敏感性，以及与刺猬信号相关的其他疾病（炎症、纤维化和免疫障碍）的治疗应用。
• ANTI-INFECTIVE BIARYL COMPOUNDS
  申请人：Jones Peter

  公开号：US20080090816A1

  公开（公告）日：2008-04-17

  Compounds represented by the formula where R 1 , R 2 , R 3 , R 4 , R 5 , and Q are as defined herein, exhibit activity against infectious pathogens.
• TLR7/8 ANTAGONISTS AND USES THEREOF
  申请人：Merck Patent GmbH

  公开号：US20200316051A1

  公开（公告）日：2020-10-08

  A treatment of disorders related to TLR7/8 overexpression or aberrant activation is provided. The disorder may include multiple sclerosis, Alzheimer's Disease, myositis, stroke, ischemia, CNS neuropathies, systemic lupus erythematosus, lupus nephritis, Sjogren's syndrome, Guillain-Barré syndrome, alcoholic hepatitis, non-alcoholic steatohepatitis, congenital heart block, autoimmune hepatitis, autoimmune pancreatitis, adult onset Still's disease, drug-induced neurological disorders, and substance addiction. A compound of Formula (I) is useful to treat such disorders.